Exchange: NASDAQ·Updated 07:30 PM EST
IMNN logo

IMNN Imunon Inc

$0.5446
$0.0295
(5.22%)
Today
Closed $0.5355
$0.0091
(1.70%)
After Hours
Mkt Cap$3.47M
Vol49,701.00

About IMNN

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
29

Bearish Sentiment

How do you feel about IMNN?

jjegglie
$IMNN I owe everyone here an apology. To friends and enemies both. I get very emotional about this company and sometimes take a tone that is less than constructive. That emotion has never once been about money lost. I've made hundreds of losing trades. No, make no mistake, my feelings come from the absolute reprobates that run this company and their disregard for everything but keeping themselves paid. Because not enough people think about how their actions hurt people. They openly steal money from investors, without a hint of regret. But far worse than that, they kill sick people with fake medicines which they already know don't work. Butter coated doxorubicin, AKA Thermodox.....yes, that Thermodox failed in the clinic the first time nearly 14 years ago. Then again in 2020, for the exact same indication. And multiple other times when it didn't even clear phase 1. And now they use it again to pump the stock clearing the way for a 400% dilution. Cont......
1
2
bxp2390
$IMNN May all have to agree with jegglie's characterization of management, he's been right all along here.
5
ALSCellTherapy
$IMNN No partnership talks ever existed. Dr. Lindborg and management lied. Yet another highly dilutive offering. Completely screwing their shareholders again.
5
ConcernedCitizen23
$IMNN say what you want it’s up to 11 phase 3 sites. It wouldn’t be growing if people weren’t talking about it behind the scenes.
4
ALSCellTherapy
$IMNN Come on Stacy and management team do something! Don’t just let this go under and bankrupt! This IL-12 platform and multi-billion blockbuster drug can’t fail and must succeed for patients and investors! Don’t go through with this S-1 offering! It is not too late to pull it back and take it off the table! There are other paths! Don’t be stupid!
4
ALSCellTherapy
$IMNN Yeah $4M market cap. It could be the end. Stacy and management have destroyed this company. Unless they have something up their sleeves.
4
bomber1
$IMNN The market is no longer looking at the scientific progress of the drug or the research behind it; instead, it is betting on the company’s failure due to a total depletion of financial resources. They have run out of money, and the market no longer believes they will be able to complete the clinical trials. Unfortunately, the billions of dollars squandered by Tardugno during his time as CEO are now taking their toll on the company. Any other firm could effectively hold them hostage, dictating terms in exchange for a pittance—a mere few million dollars. With their reputation in tatters, they face a stark choice: their continued existence is now entirely dependent on the terms set by a "Big Pharma" company. It is staggering to think that, just a few years ago, they had hundreds of millions of dollars in cash—funds that would have been incredibly useful today. Sadly, Tardugno spent it all, leaving the company completely high and dry.
4
ConcernedCitizen23
$IMNN last year they put out an S-1 and then cancelled it leading to the stock going up 10x for a month.
3
Beyonder44
$IMNN beautiful leg, increased my position here. Should be a good paycheck either end of week or upon earnings call.
3
jjegglie
$IMNN Shares outstanding on etrade up by 1 million this week. 16 % dilution. All to keep sleazy statborg, turd-ugno, blotchy, failure and the rest from missing their boat and country club payments.
2
Imran47
$IMNN • National Cancer Institute (NCI) Collaboration. In September 2026, IMUNON secured a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, under which the NCI assumed regulatory sponsorship to support further clinical development of IMNN-001.
2
bobbythek
$IMNN This stock is death by 1000 cuts for the past 15 years...Warned you many times...Reverse splits and disappointments a plenty.
2
stick_to_stocks
$IMNN absolute brutal dilution incoming. If fully executed, existing shareholders could face approximately 94% ownership dilution — an absolute bloodbath.
2
Ferryf
$IMNN IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first quarter of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit
2
ConcernedCitizen23
$IMNN btw looks like float up from 6 mill shares to 25mill shares and price still hanging in there. I guess it could have been much worse
2
jjegglie
$IMNN This is the part where the hard core zealot longs typically take their balls and slink away silently.
2
TheILLUMINIST
$IMNN Time to fluff up and rearrange your tax harvesting cushions boys. IMNN is nothing more than an over stuffed sofa.
1
Ferryf
$IMNN continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer,” said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease. We believe the OVATION 3 study is well positioned, with a broad patient population, two planned interim analyses, and a development strategy designed to support efficient execution and evaluation of the treatment’s potential benefit.” We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange.
1
Ferryf
$IMNN FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 Net loss available to common shareholders for the nine months ended September 30, 2026 was $10.9 million, or $2.01 per share, compared with a net loss of $10.3 million, or $5.53 per share, for the same period of 2025. Operating expenses were $10.5 million for the nine months ended September 30, 2026, compared with $10.4 million for the same period of 2025. Research and development expenses increased to $5.6 million for the nine months ended September 30, 2026, compared with $5.3 million in the same period of 2025. Clinical costs associated with the OVATION studies of $0.8 million were flat with the comparable period in 2025, and manufacturing and clinical supply costs supporting the OVATION and MRD programs increased to $3.3 million from $3.0 million, partially offset by lower costs associated with the MRD Study and the closeout of the OVATION 2 Study. General and administrative expenses were $5.0 million
1
STONKONAUT_TRADING
$IMNN $INO $IMNN could see a pop from INOs approval for plasmid drug also involved with plasmids per Google search…
1

Advertisement|Remove ads.